<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "epirubicin inj VIAL">
<dose><value>100</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>2 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
</frequency>
<instruction><value>DAY 1 of 21. Administer by direct injection over at least 3 minutes.</value>
</instruction>
<volume><value>25 mL</value>
<value>5 mL</value>
</volume>
<units><value>mg/m2</value>
</units>
<Population><value>Fluorouracil, Epirubicin, Cyclophosphamide (FEC) followed by DOCEtaxel. Breast Cancer (NEOADJUVANT Treatment).</value>
<value>Fluorouracil, Epirubicin, Cyclophosphamide (FEC) followed by DOCEtaxel &amp; Trastuzumab</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. MAX lifetime epirubicin dose: a) No risk factors: 1000 mg/m2, b) In combination with previous thoracic radiation or anthracycline, anthracenedione or cyclophosphamide treatment: 650 mg/m2.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3383</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>